Published: June 10, 2022 | Tags: BeiGene, Tislelizumab, NMPA, Approval, Nasopharyngeal Cancer
Amarin’s Vazkepa (icosapent ethyl) Receives NICE Recommendation for the Treatment of Cardiovascular Disease
Published: June 10, 2022 | Tags: Amarin, Vazkepa, icosapent ethyl, NICE, Recommendation, Cardiovascular Disease
Everest Medicines’ Trodelvy (sacituzumab govitecan) Receives NMPA’s Approval as 2L Treatment of Metastatic Triple-Negative Breast Cancer
Published: June 10, 2022 | Tags: Everest Medicines, Trodelvy, sacituzumab govitecan, NMPA, Approval, Metastatic Triple-Negative Breast Cancer
AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at EHA 2022
Published: June 10, 2022 | Tags: AbbVie, P-III, CLL14 Trial, Venclyxto, Venclexta, Chronic Lymphocytic Leukemia, EHA, 2022
Adverum Reports Three-Year Results of ADVM-022 in (OPTIC) Study for the Treatment of Wet Age-Related Macular Degeneration
Published: June 10, 2022 | Tags: Adverum, ADVM-022, OPTIC Study, Wet, Age-Related Macular Degeneration
Olema Entered into an Exclusive Worldwide License Agreement with Aurigene to Develop and Commercialize Novel Cancer Therapies
Published: June 10, 2022 | Tags: Olema, Aurigene, Cancer, Palbociclib, OP-1250
STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions
Published: June 9, 2022 | Tags: STADA , Alvotech, AVT02, biosimilar, adalimumab, Inflammatory Conditions
Takeda Presents Results of TAK-003 in P-III (TIDES) Trial for the Prevention of Dengue at NECTM8 2022
Published: June 9, 2022 | Tags: Takeda, TAK-003, P-III, TIDES Trial, Dengue, NECTM8, 2022
Vertex’s Inaxaplin (VX-147) Receives the US FDA’s Breakthrough Therapy Designation & EMA’s PRIME Designation for APOL1-Mediated FSGS & AMKD
Published: June 9, 2022 | Tags: Vertex, Inaxaplin, VX-147, US, FDA, Breakthrough Therapy Designation, EMA, PRIME Designation, APOL1-Mediated, FSGS, AMKD
Abbott Reports Results of MitraClip & TriClip Device in Multiple Studies for the Treatment of Patients with Heart Failure
Published: June 9, 2022 | Tags: Abbott, MitraClip, TriClip Device, Heart Failure
Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Australia, Canada
Published: June 9, 2022 | Tags: Immunocore, Kimmtrak, tebentafusp, Approval, Uveal Melanoma, UK, Australia, Canada
AstraZeneca Reports Results of Evusheld (tixagevimab and cilgavimab) in P-III (TACKLE) Trial for the Treatment of COVID-19
Published: June 9, 2022 | Tags: AstraZeneca, Evusheld, tixagevimab, cilgavimab, P-III, TACKLE Trial, COVID-19
Moderna Reports Results of Bivalent Booster mRNA -1273.214 in P-II/III Trial Demonstrated Superior Antibody Response Against Omicron
Published: June 8, 2022 | Tags: Moderna, Bivalent, Booster, mRNA -1273.214, P-II/III Trial, Omicron
Roche’s Lunsumio (mosunetuzumab) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: June 8, 2022 | Tags: Roche, Lunsumio, mosunetuzumab, EC, Approval, Follicular Lymphoma
SeaStar Medical and LMF Published Results of Selective Cytopheretic Device in (Pilot SCD 005) Study for COVID-19 in SCCM 2022, Critical Care Explorations
Published: June 8, 2022 | Tags: SeaStar Medical, Selective Cytopheretic Device, Pilot SCD 005 Study, COVID-19, SCCM, 2022
Sanofi’s Dupixent (dupilumab) Receives the US FDA’s Approval for the Treatment of Atopic Dermatitis in Children Aged 6 months to 5 years
Published: June 8, 2022 | Tags: Sanofi, Dupixent, dupilumab, US, FDA, Approval, Atopic Dermatitis
Merck and Ridgeback Report Results of Lagevrio (molnupiravir) in P-III (MOVe-OUT) Trial for the Treatment of COVID-19
Published: June 8, 2022 | Tags: Merck, Ridgeback, Lagevrio, molnupiravir, P-III, MOVe-OUT Trial, COVID-19
Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gliomas at ASCO 2022
Published: June 8, 2022 | Tags: Novartis, Tafinlar, dabrafenib, Mekinist, trametinib, P-II/III, TADPOLE Trial, BRAF V600, Low-Grade Gliomas, ASCO, 2022
GSK’s Priorix Receives the US FDA’s Approval for the Prevention of Measles, Mumps and Rubella in Patients Aged ≥12 Months
Published: June 7, 2022 | Tags: GSK, Priorix, US, FDA, Approval, Measles, Mumps, Rubella
Eli Lilly Reports Results of Lebrikizumab in P-III (ADvocate 1 & 2) Trial for the Treatment of Atopic Dermatitis
Published: June 7, 2022 | Tags: Eli Lilly, Lebrikizumab, P-III, ADvocate 1, ADvocate 2 Trial, Atopic Dermatitis
Abbott Presents Results of Freestyle Libre 3 System for the Treatment of Type 1 or Type 2 Diabetes at ADA 2022
Published: June 7, 2022 | Tags: Abbott, Freestyle Libre 3 System, Type 1, Type 2 Diabetes, ADA, 2022
Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for the Treatment of Rheumatoid Arthritis
Published: June 7, 2022 | Tags: Amgen’s Riabni, biosimilar, rituximab, US, FDA, Approval, Rheumatoid Arthritis
BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Trial for mNSCLC
Published: June 7, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, P-III, CheckMate -9LA, CheckMate -227 Trial, mNSCLC
Biogen Entered into a License and Collaboration Agreement with Alectos to Develop and Commercialize AL01811 for Parkinson’s Disease
Published: June 7, 2022 | Tags: Biogen, Alectos, AL01811, Parkinson’s Disease
Yumanity Signs a Purchase Agreement with Janssen for YTX-7739 & Reverse Merged with Kineta to Advance KVA12.1
Published: June 6, 2022 | Tags: Yumanity, Purchase Agreement, Janssen, YTX-7739, Kineta, KVA12.1
AstraZeneca Presents Results of Calquence (acalabrutinib) in P-III (ELEVATE-TN) Trial as 1L Treatment of Chronic Lymphocytic Leukaemia at ASCO 2022
Published: June 6, 2022 | Tags: AstraZeneca, Calquence, acalabrutinib, P-III, ELEVATE-TN Trial, Chronic Lymphocytic Leukaemia, ASCO, 2022
Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System Demonstrated Improved Glycemic Outcomes in Children with Type 1 Diabetes at ADA 2022
Published: June 6, 2022 | Tags: Insulet, Omnipod 5 Automated Insulin Delivery System, Glycemic Outcomes, Type 1 Diabetes, ADA, 2022
Biogen and Bio-Thera Solutions Present Results of BIIB800 (biosimilar, tocilizumab) in P-III Trial for Rheumatoid Arthritis at EULAR 2022
Published: June 6, 2022 | Tags: Biogen, Bio-Thera Solutions, BIIB800, biosimilar, tocilizumab, P-III Trial, Rheumatoid Arthritis, EULAR, 2022
Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-716) Trial for the Treatment of Resected Stage IIB or IIC Melanoma at ASCO 2022
Published: June 6, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-716 Trial, Resected, Stage IIB, IIC, Melanoma, ASCO, 2022
Eli Lilly Publishes Results of Tirzepatide in P-III (SURMOUNT-1) Trial for the Treatment of Obesity or Overweight in the NEJM
Published: June 6, 2022 | Tags: Eli Lilly, Tirzepatide, P-III, SURMOUNT-1 Trial, Obesity, Overweight, NEJM
Related Post: PharmaShots Weekly Snapshots (May 30 – June 03, 2022)
